88 Results for "

Map4

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "Map4" in MCE Product Catalog:

Cat. No.: HY-P701801
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MINK1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase 6; Misshapen Like Kinase 1; MapK/ERK Kinase Kinase Kinase 6; Map4K6; MEK Kinase Kinase 6; MINK; MEKKK 6; YSK2; Non-Specific Serine/Threonine Protein Kinase; B55; Misshapen-Like Kinase 1 (Zebrafi
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701645
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TNIK; Map4K7; TRAF2 And NCK Interacting Kinase; Non-Specific Serine/Threonine Protein Kinase; KIAA0551; MRT54; TRAF2 And NCK-Interacting Protein Kinase
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701646
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TNIK; Map4K7; TRAF2 And NCK Interacting Kinase; Non-Specific Serine/Threonine Protein Kinase; KIAA0551; MRT54; TRAF2 And NCK-Interacting Protein Kinase
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-147141A
HS-276 hydrochloride is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 hydrochloride shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 hydrochloride reduces the expression of TNF, IL-6, and IL-1β. HS-276 hydrochloride can be used for rheumatoid arthritis (RA) research .
loading...
    loading...
Cat. No.: HY-147141B
HS-276 formic is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 formic shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 formic reduces the expression of TNF, IL-6, and IL-1β. HS-276 formic can be used for rheumatoid arthritis (RA) research .
loading...
    loading...
Cat. No.: HY-W207224
CAS No.: 287177-12-2
Target:  

MAP4K

F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
loading...
    loading...
Cat. No.: HY-179338
Research Areas:  

Cancer

HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC50 value of < 5 nM. HPK1-IN-65 inhibits HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC50 of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC50 of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research .
loading...
    loading...
Cat. No.: HY-184792
Research Areas:  

Cancer

CA/PRAK-IN-1 is a dual inhibitor of carbonic anhydrase (Carbonic Anhydrase) and PRAK, with a Ki of 20.1 nM against hCA IX and 16.4 nM against hCA XII. CA/PRAK-IN-1 exhibits inhibitory activity against YES1 kinase, BTK, and MAP4K3. CA/PRAK-IN-1 induces G0/G1 phase arrest of the cancer cell cycle, inhibits DNA synthesis, disrupts hypoxia-driven survival pathways, promotes cell death, and shows broad-spectrum cytotoxicity against tumor cells. CA/PRAK-IN-1 can be used in research on various cancers including leukemia, colon cancer, melanoma, and renal cancer .
loading...
    loading...